anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided are a fenugreek cold-damp-dispelling fricassee seasoning and a preparation method therefor. The fricassee seasoning is prepared from traditional Chinese medicine powder, meat meal and chilli powder according to a weight ratio of 15:4:1. The traditional Chinese medicine powder is prepared from, by weight, 35-45 parts of fenugreek, 21-26 parts of Chinese banana root, 21-26 parts of bock greenbrier rhizome, 15-18 parts of maize, 15-18 parts of herba inulae cappae, 15-18 parts of pine mushroom, 15-18 parts of gracilaria, 8-13 parts of Jiangxi christina loosestrife herb, 8-13 parts of semen cassiae sopherae, 8-13 parts of cowpea, 8-13 parts of acronychia pedunculata and 8-13 parts of amaranthus viridis. The meat meal is prepared from rabbit meat, chicken, duck meat, goose meat and beef. The chilli powder is prepared from capsicum frutescens, shuanshuan pepper, pod pepper, capsicum annuum and ornamental pepper. The provided fricassee seasoning has functions of dispelling cold-damp, tonifying kidney yang and treating cold hernia after long-term consumption.
The current study enrolled subjects who already participated in the 2015 study (n=109) at the National Taiwan University Hospital Bei-Hu Branch (NTUHBB). Subjects will be maintained in their original integrated care group (ICG, target n=50) and muscle training group (MTG, target n=50) when possible. If target sample size is not reached, clinic patients are screened for high risk of fall, osteoporosis/fracture by standardized questionnaires or FRAX for enrollments. New participants are randomized into the ICG and MTG groups. Other than assessments provided in 2015, digital photography on posture and low back pain assessments are done in 2016. All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with more focus on central muscle groups. ICG subjects received once weekly group exercise while MTG subjects received twice weekly machine-based resistance training on major muscle groups. Major outcomes were muscle mass (measured by bio-impedance analysis), grip strength, walking speed, and lower leg extension power, Chinese version of Oswestry Disability Index v 2.1 score (for low back pain), and spine curve angle (by photography) at baseline and after 12-weeks of intervention.
<P>PROBLEM TO BE SOLVED: To provide a carbohydrate digestive enzyme inhibitor in the presence of of diet experience, with its action not be inhibited by other actions.  <P>SOLUTION: The carbohydrate digestive enzyme inhibitor comprises extract of a plant belonging to Juglandaceae such as Jaglans regia, Juglans mandshurica or walnut. A food composition is obtained by including this inhibitor. For this inhibitor, the extract is prepared by defatting followed by extraction of preferably seeds of the plant, especially preferably kernels, further preferably walnut kernels with a polar solvent followed by refining through liquid/liquid extraction, column chromatography or the like. This inhibitor is excellent in inhibitory action for α-glucosidase including sucrase and maltase and amylase.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
ETHNOPHARMACOLOGICAL RELEVANCE: Psoriasis is a chronic inflammation and relapsing disease that affected approximately 100 million individuals worldwide. In previous clinical study, it was observed that the topical application of Si Cao Formula (SCF) ameliorated psoriasis skin lesions and reduced the recurrence rate of patients over a period of three months. However, the precise mechanism remains unclear.
AIM OF THE STUDY: The objective of this study was to assess the effectiveness and safety of SCF in patients diagnosed with psoriasis and explore the molecular mechanisms that contribute to SCF's therapeutic efficacy in psoriasis treatment.
MATERIALS AND METHODS: A randomized, controlled, and pilot clinical study was performed. This study assessed 30 individuals diagnosed with mild to moderate plaque psoriasis. 15 of them underwent local SCF treatment, the others received calcipotriol intervention. The outcome measure focused on Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and recurrence rate. In addition, IMQ-induced psoriasis-like mice model were used to assess the impact of SCF on ameliorating epidermal hyperplasia, suppressing angiogenesis, and modulating immune response. Furthermore, we performed bioinformatics analysis on transcriptome data obtained from skin lesions of mice model. This analysis allowed us to identify the targets and signaling pathways associated with the action of SCF. Subsequently, we conducted experimental validation to confirm the core targets.
RESULTS: Our clinical pilot study demonstrated that SCF could ameliorate skin lesions in psoriasis patients with comparable efficacy of calcipotriol in drop of PASI and DLQI scores. SCF exhibited a significantly reduced recurrence rate within 12 weeks (33.3%). Liquid Chromatography Mass Spectrometry (LC-MS) identified 41 active constituents of SCF (26 cations and 15 anions). Animal experiments showed SCF ameliorates the skin lesions of IMQ-induced psoriasis like mice model and suppresses epidermal hyperkeratosis and angiogenesis. There were 845 up-regulated and 764 down-regulated DEGs between IMQ and IMQ + SCF groups. GO analysis revealed that DEGs were linked to keratinization, keratinocyte differentiation, organic acid transport epidermal cell differentiation, and carboxylic acid transport interferon-gamma production. KEGG pathway analysis showed that SCF may play a vital part through IL-17 and JAK/STAT signaling pathway. In addition, SCF could reduce the number of positive cells expressing PCNA, CD31, pSTAT3, CD3, and F4/80 within the epidermis of psoriatic lesions, as well as the expression of Il-17a and Stat3 in IMQ-induced psoriasis mice.
CONCLUSIONS: Our research suggests that SCF serves as a reliable and efficient local approach for preventing and treating psoriasis. The discovery of plausible molecular mechanisms and therapeutic targets associated with SCF may support its broad implementation in clinical settings.
Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
The control group will get a 6-week therapist-guided online stress recovery intervention without an intervention plan. The control group will participate in the program at the same time as the intervention group.
Patients in the control group will receive standard care; All patients should attend a 1-hour face-to-face group pre-operative education class. Patients in either group will have access to a helpline where they can speak to a nurse to discuss any problems or concerns. All patients will also receive a follow-up phone call from a nurse within 5 days of discharge to check their progress and will attend a 6-12 week follow-up clinic with their surgeon.
FIELD: medicine; oncology.SUBSTANCE: group of inventions is intended for immunotherapy of malignant tumors. Pharmaceutical composition is a vaccine inducing formation of anti-tumor antibodies. Vaccine contains immunogenic glycoconjugate Globo-H-KLH (OBI-822), in which molecules of tumor antigen Globo-H are covalently linked to molecules of structural subunits of hemocyanin KLH by one or more residues of amino acids. Said composition has an epitope ratio of Globo-H molecule / molecule of structural subunit KLH in range from 750 to 3000. In one embodiment, the Globo-H molecule is bound to KLH by covalent bonding with 4-(4-maleimidomethyl)cyclohexane-1-carboxylhydrazide (MMCCH). In another version, said composition may contain an adjuvant α-galactosylceramide(α-GalCer). In one embodiment, the method of treating a malignant tumor involves administering to a patient a therapeutically effective amount of said pharmaceutical composition. In another version, said composition is administered to an individual in order to obtain monoclonal antibodies for therapeutic or diagnostic use.EFFECT: group of inventions enables to elicit a high level of the immune response directed to Globo-H.46 cl, 7 tbl, 38 dwg, 9 ex
The present disclosure introduces safe and effective pharmaceutical formulations for intranasal delivery. Specifically, the present disclosure introduces the safe clinical use of bile acids or salts thereof as an enhancer to exhibit improved bioavailability and tissue tolerance. In several embodiments, pharmaceutical formulations including bile acids or salts thereof are provided. In several embodiments, the formulations are suitable and/or configured for the intranasal (IN) delivery, methods of manufacturing such formulations, and methods of treating patients using such formulations. The pharmaceutical formulations comprising bile acids, salts of bile acids, and/or combinations thereof. In several embodiments, bile acids, salts of bile acids, and/or combinations thereof are configured for use as absorption enhancers.
Participants will receive unesbulin orally twice weekly in combination with dacarbazine IV once every 21 days. The first participant will receive dacarbazine 1000 mg/m\^2 IV every 21 days in combination with unesbulin 200 mg tablet orally twice weekly. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose DLT information from all participants previously treated. Participants will receive unesbulin 300 mg twice weekly in combination with dacarbazine in the expansion cohort. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex and multifactorial disease. Dark tea exhibits great potential for various bioactivities for metabolic health. In this study, we aimed to evaluate therapeutic effects and the underlying mechanisms of dark tea wine (DTW) on MASLD with obesity. A rat model of MASLD was established by high-fat diet and administered with different doses of DTW as an intervention. The biomarkers of lipid metabolism and oxidative stress in rats were tested. The weight of organs and adipose tissues and the expressions of nuclear factor erythroid 2-like 2 (Nrf2) and heme oxygenase-1 (HO-1) were investigated based on the pathology and western blot analysis. We found that DTW enhanced antioxidant capacity via activating the Nrf2/HO-1 signaling pathway, further markedly triggering inhibition of weight gain, reduction of lipid dysfunction, and improvement of pathological characteristics to ameliorate MASLD induced by high-fat diet. These results suggest that DTW is a promising functional supplement for prevention and treatment of MASLD and obesity.
Risk Summary

There are no data on the presence of voxelotor in human milk, the effects on the breastfed child, or the effects on milk production. Voxelotor was detected in milk in lactating rats. Plasma concentrations of voxelotor in pregnant rats were higher than the concentration in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The concentration of voxelotor in animal milk does not necessarily predict the concentration of drug in human milk. Because of the potential for serious adverse reactions in the breastfed child, including changes in the hematopoietic system, advise patients that breastfeeding is not recommended during treatment with OXBRYTA, and for at least 2 weeks after the last dose.
INTRODUCTION: The arts and humanities (AH) have transformative potential in medical education. Research suggests that AH-based pedagogies may facilitate both personal and professional transformation in medical learners, which may then further enhance the teaching and learning of social advocacy skills. However, the potential for such curricula to advance social advocacy training remains under-explored. Therefore, we sought to identify how AH may facilitate transformative learning of social advocacy in medical education.
METHODS: Building upon previous research, we conducted a critical narrative review seeking examples from the literature on how AH may promote transformative learning of social advocacy in North American medical education. Through a search of seven databases and MedEdPORTAL, we identified 11 articles and conducted both descriptive and interpretative analyses of their relation to key tenets of transformative learning, including: disorientation/dissonance, critical reflection, and discourse/dialogue.
RESULTS: We found that AH are used in varied ways to foster transformative learning in social advocacy. However, most approaches emphasize their use to elicit disorientation and dissonance; there is less evidence in the literature regarding how they may be of potential utility when applied to disorienting dilemma, critical reflection, and discourse/dialogue.
DISCUSSION: The tremendous potential of AH to foster transformative learning in social advocacy is constrained due to minimal attention to critical reflection and dialogue. Future research must consider how novel approaches that draw from AH may be used for more robust engagement with transformative learning tenets in medical education.
Developed for medical treatment at a distance, using Medical Artificial Intelligence (MAI) and Telemedicine. The patient (P), using her/his computer, tablet, laptop or through SMS technology using her/his mobile phone, send health information to a control center (C) hosted in the web and in an integrated computer with dedicated software (S) developed with algorithms and filters based in medical artificial intelligence. The software (S) form a database (BD) personalized in clinical analysis, diagnosis, drugs prescription and the proposed treatment to be administered to said patient (P). The detailed history by software (S) in the database (DB) is stored in the control center (C), indicating physicians (MC) also registered according to the specialty to the patient (P), defined by the clinical results obtained. The physician (P) accesses then, from her/his computer, the database (BD) and being with the results of the patient (P) displayed on the screen, check them, validating the attendance and thus beginning to monitor remotely in a custom and legalized manner (under supervision of the control central (C)), requesting and sending information, medical tests, prescriptions and administering prescription drugs in encrypted procedure accessed only by implanted passwords with translation intra software and full mobility, whether via mobile or desktop, independent of the region of the planet. Through the system, physician (P) treatment is speeded on a large scale and in a personalized way to the patient (P), whether in public or private networks.
BMN 190 is a recombinant form of human tripeptidyl peptidase 1 (TPP1), the enzyme deficient in patients with CLN2 disease (also known as classical late-infantile CLN2, cLINCL, or Jansky-Bielschowsky disease), a form of Batten Disease. As an enzyme replacement therapy (ERT), BMN 190 is designed to help restore TPP1 enzyme activity. The Phase 1/2 study (190-201) evaluated the efficacy and safety of a 300 mg dose of BMN 190 administered every other week (qow) to patients with CLN2. The dose and regimen for this study (190-202) are based on the results of the 190-201 study. The rationale for this phase 2 extension study is to provide patients who complete the 190-201 study with the option to continue BMN 190 treatment. The 190-202 study is an open label extension protocol to assess long-term safety and efficacy.
FIELD: veterinary science. SUBSTANCE: invention relates to vaccine raised against swine and reproductive and respiratory syndrome that has an active component and special additions. Vaccine has parainfluenza virus type 2, in part, strain ESR as live, dead, attenuated or obtained by recombinant technology form being as a whole or part and fragment as an active substance and taken in the effective amount. Vaccine is used for producing immunity against the swine reproductive and respiratory syndrome in animals. EFFECT: enhanced effectiveness of vaccine. 3 ex
THALOMID is contraindicated in females who are pregnant. THALOMID can cause fetal harm when administered to a pregnant female [see Boxed Warning, Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. THALOMID is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects, even after a single dose [see Boxed Warning]. Mortality at or shortly after birth has been reported in about 40% of infants. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus. If pregnancy occurs during THALOMID treatment, the drug should be discontinued immediately.
The invention relates to the technical field of analysis and detection of traditional Chinese medicines, in particular to a glaucescent fissistigma root extract, a preparation method and application thereof. According to the invention, the content change of luteolin and the dry paste rate of the Wula grass extract are taken as evaluation indexes, an orthogonal optimization test is established to establish an optimal extraction method of Wula grass, and the Wula grass liquid medicine is developed based on the optimal extraction method of Wula grass. The quality evaluation method of the invention evaluates the quality of the uraria herbal medicine liquid by a plurality of detection means, including character analysis, thin-layer chromatography qualitative analysis and high performance liquid chromatography for measuring the content of luteolin. The antibacterial and anti-inflammatory effects of the uraria liquid medicine are examined by a rat colpitis model. Experiments prove that the method is stable and reliable, can evaluate the quality of the uraria herbal medicine liquid more comprehensively, and has good antibacterial and anti-inflammatory effects. The glaucescent fissistigma root extract prepared by the invention has the effect of treating colpitis through animal efficacy.
The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM \< 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestin to reduce the risk of endometrial cancer. 

Generally, a woman without a uterus does not need to take a progestin in addition to her estrogen therapy. In some cases, however, hysterectomized women who have a history of endometriosis may need a progestin [see Warnings and Precautions (5.2), (5.14)]. 

Use estrogen-alone, or in combination with a progestin, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Reevaluate postmenopausal women periodically as clinically appropriate to determine if treatment is still necessary.

ELESTRIN is applied onto the skin in a thin layer. The recommended area of application is the upper arm to shoulder (approximately 320 cm2).
Ten healthy volunteers, aged 18 to 65 years will be recruited. Each subject will be studied on six occasions one week apart. On each visit, a baseline serum sample will be drawn from each subject. In a randomized way all subjects will receive the following meals in their successive weekly visits: Option 1 High protein mixed meal in capsules that break down in the stomach, Option 2 High protein mixed meal in capsules that break down in the distal small bowel, Option 3 High fat mixed meal in capsules that break down in the stomach, Option 4 High fat mixed meal in capsules that break down in the distal small bowel, Option 5 High CHD mixed meal in capsules that break down in the stomach, Option 6 High CHD mixed meal in capsules that break down in the distal small bowel. On the same day, all subjects will be offered standard ad libitum meal to measure their food consumption. After 3 hours (i.e. at 12:00) another blood sample will be drawn. All subjects will be asked to rate their appetite on a Visual Analogue Scale (VAS). Upon VAS completion the subjects will be allowed to go home.
INTRODUCTION: Skin injuries represent a prevalent form of physical trauma, necessitating effective therapeutic strategies to expedite the wound healing process. Hesperidin, a bioflavonoid naturally occurring in citrus fruits, exhibits a range of pharmacological attributes, including antimicrobial, antioxidant, anti-inflammatory, anticoagulant, and analgesic properties. The main objective of the study was to formulate a hydrogel with the intention of addressing skin conditions, particularly wound healing.
METHODS: This research introduces a methodology for the fabrication of a membrane composed of a Polyvinyl alcohol - Sodium Alginate (PVA/A) blend, along with the inclusion of an anti-inflammatory agent, Hesperidin (H), which exhibits promising wound healing capabilities. A uniform layer of a homogeneous solution comprising PVA/A was cast. The process of crosslinking and the enhancement of hydrogel characteristics were achieved through the application of gamma irradiation at a dosage of 30 kGy. The membrane was immersed in a Hesperidin (H) solution, facilitating the permeation and absorption of the drug. The resultant system is designed to deliver H in a controlled and sustained manner, which is crucial for promoting efficient wound healing. The obtained PVA/AH hydrogel was evaluated for cytotoxicity, antioxidant and free radical scavenging activities, anti-inflammatory and membrane stability effect. In addition, its action on oxidative stress, and inflammatory markers was evaluated on BJ-1 human normal skin cell line.
RESULTS AND DISCUSSION: We determined the effect of radical scavenging activity PVA/A (49 %) and PVA/AH (87%), the inhibition of Human red blood cell membrane hemolysis by PVA/AH (81.97 and 84.34 %), hypotonicity (83.68 and 76.48 %) and protein denaturation (83.17 and 85.8 %) as compared to 250 μg/ml diclofenac (Dic.) and aspirin (Asp.), respectively. Furthermore, gene expression analysis revealed an increased expression of genes associated with anti-oxidant and anti-inflammatory properties and downregulated TNFα, NFκB, iNOS, and COX2 by 67, 52, 58 and 60%, respectively, by PVA/AH hydrogel compared to LPS-stimulated BJ-1 cells. The advantages associated with Hesperidin can be ascribed to its antioxidant and anti-inflammatory attributes. The incorporation of Hesperidin into hydrogels offers promise for the development of a novel, secure, and efficient strategy for wound healing. This innovative approach holds potential as a solution for wound healing, capitalizing on the collaborative qualities of PVA/AH and gamma irradiation, which can be combined to establish a drug delivery platform for Hesperidin.
After the health education（such as dietary adjustment for FD patients）, the participants will be followed up for 4 weeks. At the end of the follow-up, the patients could be given free acupuncture treatment (the invention will be similar with that of the Three times a week group) for 4 weeks at will.